EPIC: A phase III randomized, open-label study of ponatinib versus imatinib in adult patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Jeffrey H. Lipton
Consultant or Advisory Role - ARIAD
Stock Ownership - ARIAD
Research Funding - ARIAD
Michael W. N. Deininger
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Incyte; Novartis
Honoraria - ARIAD; Bristol-Myers Squibb; Incyte; Novartis
Research Funding - Bristol-Myers Squibb; Celgene; Genzyme; Gilead Sciences; Novartis
Stephanie Lustgarten
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
Christopher D. Turner
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
Victor M. Rivera
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
Tim Clackson
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
Michele Baccarani
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva
Jorge E. Cortes
Consultant or Advisory Role - ARIAD; Pfizer; Teva
Research Funding - ARIAD; Bristol-Myers Squibb; ChemGenex; Novartis; Pfizer
Francois Guilhot
Consultant or Advisory Role - ARIAD
Honoraria - ARIAD
Andreas Hochhaus
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - ARIAD; Bristol-Myers Squibb; MSD; Novartis; Pfizer
Timothy P. Hughes
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis
Hagop M. Kantarjian
Research Funding - ARIAD; Bristol-Myers Squibb; Bristol-Myers Squibb; Novartis; Novartis; Pfizer; Pfizer
Neil P. Shah
Consultant or Advisory Role - ARIAD
Research Funding - ARIAD; Bristol-Myers Squibb
Moshe Talpaz
Consultant or Advisory Role - ARIAD
Research Funding - ARIAD
Frank G. Haluska
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD